• 1
    Gum JR Jr. Mucin genes and the protein they encode: structure, diversity, and regulation. Am J Respir Cell Mol Biol 1992; 7: 55764.
  • 2
    Barnd DL, Lan MS, Metzgar RS, Finn OJ. Specific major histocompatibility complex-unrestricted recognition of tumor associated mucins by human cytotoxic T cells. Proc Natl Acad Sci USA 1989; 86: 715963.
  • 3
    Rughetti A, Turchi V, Ghetti CA, Scambia G, Panici PB, Roncucci G, Mancuso S, Frati L, Nuti M. Human B-cell immune response to the polymorphic epithelial mucin. Cancer Res 1993; 53: 24579.
  • 4
    Hinoda Y, Nakagawa N, Nakamura H, Makiguchi Y, Itoh F, Adachi M, Yabana T, Imai K, Yachi A. Detection of a circulating antibody against a peptide epitope on a mucin core protein, MUC1, in ulcerative colitis. Immunol Lett 1993; 35: 1638.
  • 5
    Kotera Y, Fontenot JD, Pecher G, Metzgar RS, Finn OJ. Humoral immunity against a tandem repeat epitope of human mucin MUC-1 in sera from breast, pancreas, and colon cancer patients. Cancer Res 1994; 54: 285660.
  • 6
    von Mensdorff-Pouilly S, Verstraeten AA, Kenemans P, Snijdewint FG, Kok A, Van Kamp GJ, Paul MA, Van Diest PJ, Meijer S, Hilgers J. Survival in early breast cancer patients is favorably influenced by a humoral immune response to polymorphic epithelial mucin. J Clin Oncol 2000; 18: 57483.
  • 7
    Richards ER, Devine PL, Quin RJ, Fontenot JD, Ward BG, McGuckin MA. Antibodies reactive with the protein core of MUC1 mucin are present in ovarian cancer patients and healthy women. Cancer Immunol Immunother 1998; 46: 24552.
  • 8
    Nakamura H, Hinoda Y, Nakagawa N, Makiguchi Y, Itoh F, Endo T, Imai K. Detection of circulating anti-MUC1 mucin core protein antibodies in patients with colorectal cancer. J Gastroenterol 1998; 33: 35461.
  • 9
    Treon SP, Mollick JA, Urashima M, Teoh G, Chauhan D, Ogata A, Raje N, Hilgers JH, Nadler L, Belch AR, Pilarski LM, Anderson KC. Elevated soluble MUC1 levels and decreased anti-MUC1 antibody levels in patients with multiple myeloma. Blood 2000; 96: 314753.
  • 10
    TNM: classification of malignant tumors. 5th ed. In: SobinLH, WittekindCh, eds. New York: Wiley-Liss, Inc., 1997.
  • 11
    Hinoda Y, Nakagawa N, Ohe Y, Kakiuchi H, Tsujisaki M, Imai K, Yachi A. Recognition of the polypeptide core of mucin by monoclonal antibody MUSE11 against an adenocarcinoma-associated antigen. Jpn J Cancer Res 1990; 81: 12069.
  • 12
    Takahashi T, Makiguchi Y, Hinoda Y, Kakiuchi H, Nakagawa N, Imai K, Yachi A. Expression of MUC1 on myeloma cells and induction of HLA-unrestricted cytotoxic T lymphocytes against MUC1 from a multiple myeloma patient. J Immunol 1994; 153: 21029.
  • 13
    Satoh S, Hinoda Y, Burdick MD, Imai K, Hollingsworth MA. Enhancement of metastatic properties of pancreatic cancer cells by transfer of MUC1 gene encoding an anti-adhesion molecule. Int J Cancer 2000; 88: 50718.
  • 14
    Sandrin MS, Vaughan HA, Xing PX, McKenzie IF. Natural human anti- Galα(1,3)Gal antibodies react with human mucin peptides. Glycoconjugate J 1997; 14: 97105.
  • 15
    Kurtenkov O, Miljukhina L, Smorodin J, Klaamas K, Bovin N, Ellamaa M, Chuzmarov V. Natural IgM and IgG antibodies to Thomsen-Friedenreich (T) antigen in serum of patients with gastric cancer and blood donors—relation to Lewis (a, b) histo-blood group phenotype. Acta Oncol 1999; 38: 93943.
  • 16
    Kohno N, Kyoizumi S, Awaya Y, Fukuhara H, Yamakido M, Akiyama M. New serum indicator of interstitial pneumonitis activity. Sialylated carbohydrate antigen KL-6. Chest 1989; 96: 6873.
  • 17
    Kohno N, Inoue Y, Hamada H, Fujioka S, Fujino S, Yokoyama A, Hiwada K, Ueda N, Akiyama M. Difference in sero-diagnostic values among KL-6-associated mucins classified as cluster 9. Int J Cancer Suppl 1994; 8: 813.
  • 18
    von Mensdorff-Pouilly S, Petrakou E, Kenemans P, van Uffelen K, Verstraeten AA, Snijdewint FG, van Kamp GJ, Schol DJ, Reis CA, Price MR, Livingston PO, Hilgers J. Reactivity of natural and induced human antibodies to MUC1 mucin with MUC1 peptides and N-acetylgalactosamine (GalNAc) peptides. Int J Cancer 2000; 86: 70212.